Published in Ther Adv Endocrinol Metab on April 01, 2013
Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes (2015) 1.05
Dual Anti-Inflammatory and Anti-Angiogenic Action of miR-15a in Diabetic Retinopathy. EBioMedicine (2016) 0.85
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med (2008) 8.82
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology (2011) 6.33
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia (2001) 4.78
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology (1998) 4.21
Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol (1998) 3.83
Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol (1996) 3.50
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29
Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med (2005) 3.19
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol (2009) 2.84
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology (2011) 2.43
Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes (1997) 2.33
Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci (2004) 1.89
Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest (2012) 1.79
Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes (2010) 1.73
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A (2008) 1.70
Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol (1999) 1.59
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol (2013) 1.55
The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology (2009) 1.47
Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes (2012) 1.36
Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes (2007) 1.34
Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol (2012) 1.31
Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care (2002) 1.30
Blindness and visual impairment in Germany: a slight fall in prevalence. Dtsch Arztebl Int (2012) 1.27
Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci (2011) 1.26
Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia (2011) 1.25
Disruption of the retinal parafoveal capillary network in type 2 diabetes before the onset of diabetic retinopathy. Invest Ophthalmol Vis Sci (2011) 1.24
Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care (2011) 1.23
Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes (2010) 1.23
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev (2009) 1.21
Intravitreal triamcinolone. Ophthalmologica (2010) 1.14
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes (2012) 1.08
Same-session functional assessment of rat retina and brain with manganese-enhanced MRI. Neuroimage (2011) 1.07
Incidence of retinopathy in type I (insulin-dependent) diabetes: association with clinical nephropathy. J Diabet Complications (1988) 0.99
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. Diabet Med (2011) 0.98
Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients. Horm Metab Res Suppl (1992) 0.96
Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina (2012) 0.94
Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol (1998) 0.92
The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol (2008) 0.89
Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2012) 0.84
The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema. Br J Ophthalmol (2007) 0.82
MRI retinovascular studies in humans: research in patients with diabetes. NMR Biomed (2008) 0.82
Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can J Ophthalmol (2009) 0.80
Type 1 diabetes in Cheshire: cardiometabolic risk factor trends (2004-2009). Prim Care Diabetes (2011) 0.78